Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoricoxib + betamethasone (Laboratorios Silanes)
- Development stage
- Phase 3
- Lead developer
- Laboratorios Silanes
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Etoricoxib + betamethasone is a fixed-dose combination (FDC) therapy developed by Laboratorios Silanes for the management of pain and inflammation. This combination pairs etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, with betamethasone, a potent synthetic corticosteroid. Etoricoxib provides targeted anti-inflammatory and analgesic effects by inhibiting the COX-2 enzyme, which is responsible for prostaglandin synthesis in response to inflammatory stimuli, while sparing the COX-1 enzyme associated with gastrointestinal protection. Betamethasone complements this action by acting as a glucocorticoid receptor agonist, modulating gene expression to suppress a wide range of inflammatory cytokines and mediators. This dual-action approach is designed to provide rapid and effective relief for acute musculoskeletal pain and inflammatory conditions.
- Other names
- Etoricoxib/Betamethasone FDCEtoricoxib/Betamethasone Silanes
02
Targets
GR (Glucocorticoid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on etoricoxib + betamethasone (Laboratorios Silanes).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoricoxib + betamethasone (Laboratorios Silanes).